Macular Degeneration

Treatment approaches covered
Intravitreal anti-VEGF treatment | Other intravitreal treatments | Photodynamic therapy | Thermal photocoagulation
Retinal radiation therapy | Transpupillary thermotherapy | Retinal surgical treatment

Details
1. Endophthalmitis
2. Individual treatments received for macular degeneration
3. Recommended to track via the Brief Impact of Vision Impairment (B_IVI) Questionnaire
4. Presence of fluid, edema, or hemorrhage

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/Macular-Degeneration
Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsors

The Working Group

Australia
Mark Gillies | University of Sydney
India
Kim Ramasamy | Aravind Eye Care System
Japan
Nagahisa Yoshimura | Kyoto University
Hiroshi Tamura | Kyoto University
Malaysia
Norfariza Ngah | Hospital Selayang
Dato Shankar

Netherlands
Caroline Klaver | Erasmus Medical Center
Singapore
Gemmy Cheung | Singapore National Eye Center
Sweden
Inger Westborg | Umeå University; Registercenter Syd/EyeNet Sweden
Switzerland
Daniel Barthelmes | University Hospital Zurich

United Kingdom
Robert Johnston | Gloucestershire Hospitals NHS Foundation Trust
Adnan Tufail | Moorfields Eye Hospital
Ian Rodrigues | St. Thomas’ Hospital
Martin McKibbin | Royal College of Ophthalmologists
Cathry Yelf | Macular Society

United States
Mark Blumenkranz | The Byers Eye Institute at Stanford University
Suzann Pershing | Stanford University;
American Academy of Ophthalmology;
VA Palo Alto Health Care System
Christina Weng | Baylor College of Medicine
Julia Haller | Wills Eye Hospital; Thomas Jefferson University

*Patient representative